-
Study aim
-
Comparing the effect of metformin and empagliflozin on cardiometabolic, anthropometric and hormonal factors of women with polycystic ovary syndrome.
-
Design
-
A clinical trial with a control group, with parallel groups, phase 3, randomized with random allocation software, is conducted on 50 patients.
-
Settings and conduct
-
This research is a clinical trial that is conducted on women aged 15 to 55 with polycystic ovary syndrome who refer to Imam Ali Shahrekord Clinic. For three months, the intervention group is treated with empagliflozin tablets and the control group is treated with metformin tablets. Before and after the intervention, anthropometric, hormonal and cardiometabolic factors are measured in both groups and compared at the end.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: women aged 15-55, polycystic ovarian syndrome
Exclusion criteria: Diabetes, pregnancy, urinary tract infection
-
Intervention groups
-
Patients are divided into 2 groups, empagliflozin group and metformin group. The intervention group received empagliflozin 10 mg tablets (Abidi company) daily for 3 months, and the control group received metformin 1000 mg tablets (Raha Daroo company) daily for three months.
-
Main outcome variables
-
Weight, body mass index, waist circumference, fasting sugar, Hba1c, total testosterone, 17-oh progesterone
AST, ALT, HOMA-IR, CRP, triglyceride, LDL, HDL, total cholesterol, fasting insulin, Dehydroepiandrosterone